APUS vs PCAR · $2.4M cap vs P/E 25, rev $33.66B
Apimeds Pharmaceuticals US, Inc. (APUS) versus PACCAR Inc (PCAR) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
PACCAR Inc (PCAR) is a farm & heavy construction machinery company listed on NASDAQ.
APUS does not have a complete income-statement cache yet.
Latest reported PCAR revenue for 2024-12-31 was $33.66B. Net income was $4.16B. Revenue was down 4.2% from 2023-12-31 to 2024-12-31. PCAR currently screens at market cap $61.75B and trailing P/E 25.0.
APUS currently screens at market cap $2.4M. PCAR currently screens at market cap $61.75B and trailing P/E 25.0.
Not investment advice. Open the APUS and PCAR stock pages for the full models.
Not investment advice.